Structure Therapeutics (GPCR) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Pipeline overview and strategy

• Focus on oral small molecule medicines for metabolic diseases, leveraging structure-based drug discovery targeting GPCRs such as GLP-1, amylin, GIP, glucagon, apelin, and LPA1 receptors.

• Lead asset GSBR-1290, an oral GLP-1 agonist, has shown 6.2–6.9% body weight loss over 12 weeks in phase IIa, with plans to initiate a 36-week phase IIb study and potential for higher dosing.

• Additional assets include an oral amylin agonist expected to enter the clinic by end of next year, and an apelin receptor agonist that is phase II-ready.

• Early-stage pipeline includes discovery efforts on GIP and glucagon receptors, and a phase I LPA1 program for idiopathic pulmonary fibrosis with data expected in the first half of 2025.

• Strategic partnerships are actively being pursued to support late-stage development and commercialization, with a focus on partners experienced in cardiometabolic diseases.

Clinical data and differentiation

• GSBR-1290 demonstrated a clean safety profile with no liver toxicity or off-target effects, and tolerability improved with slower titration and over time.

• Replacement cohort in phase IIa showed nearly 9% weight loss, attributed to enhanced clinical oversight and consistent protocols.

• Tablet formulation cohort confirmed similar efficacy and tolerability as the capsule, supporting flexibility in future studies.

• Manufacturing capacity enables production for over 120 million patients, a key differentiator versus oral peptides.

• Differentiation is based on a novel chemical scaffold, broad IP coverage, and the ability to dose beyond 120 mg for greater efficacy.

Organizational updates and financials

• Recent senior management additions include a new Chief Medical Officer and Chief Development Officer to accelerate clinical development and regulatory strategy.

• Cash position of $927 million as of Q2, providing runway through 2027 to complete phase IIb, phase III enabling activities, and manufacturing scale-up.

• IP strategy covers multiple scaffolds and generations, aiming to secure broad protection for current and future assets.

• The company is preparing for phase III readiness and strategic partnership opportunities as the pipeline advances.